Active, not recruitingEarly Phase 1NCT01189643

Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor

Studying Desmoplastic small round cell tumor

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Memorial Sloan Kettering Cancer Center
Principal Investigator
Emily Slotkin, MD
Memorial Sloan Kettering Cancer Center
Intervention
irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator(drug)
Enrollment
15 enrolled
Eligibility
1-29 years · All sexes
Timeline
20102026

Study locations (1)

Collaborators

Genentech, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01189643 on ClinicalTrials.gov

Other trials for Desmoplastic small round cell tumor

Additional recruiting or active studies for the same condition.

See all trials for Desmoplastic small round cell tumor

← Back to all trials